To accelerate the development of novel therapeutics by providing researchers with high-quality products and services for all stages of research. Powered by our team of experts in virology, immune-oncology, cell and vector engineering, and assay development, our vision is to be a leader in research services and laboratory assays to drive clinical translation of next-generation therapies.
Proprietary NIS reporter gene imaging technology for unprecedented clarity in long-term longitudinal cell and virus tracking studies in small and large animal models.
The first and only commercially available repository of recombinant oncolytic viruses encoding reporter genes for research use.
The Imanis Team
At Imanis, we put our virus engineering expertise to work for our clients and deliver exceptional customer service and meaningful, cutting edge science. The Imanis scientist is a team player who wants to dive into the details, be involved at every stage of the process, collaborate closely with other experts and help create the next breakthrough. We are always seeking intellectual curiosity, initiative, and dedication from our scientists. If putting your expertise to work sounds appealing, apply to join our growing team today at imanislife.com/careers.
Our Scientific Cofounders
Imanis was founded in 2012 by scientific cofounders, Drs. Stephen Russell, Kah-Whye Peng and Michael O’Connor, Professors at Mayo Clinic Rochester, MN. Dr. Russell was recruited to Mayo Clinic from University of Cambridge, UK, in 1998 to be the Director of a new virus and gene therapy program at Mayo. As a clinician scientist, he has a dream to develop replication competent viruses for cancer therapy. Together with Dr. Kah-Whye Peng, they built a new program and later department (Molecular Medicine) known internationally for bench to clinical translation of oncolytic virotherapies. Dr. Russell wanted a reporter gene technology that enables long term monitoring of viruses in small and large animals and in human subjects. NIS is ideal as it is nonimmunogenic, species specific NIS exist allowing for easy transition from mouse to large animal models, is not harmful the normal physiology of the cell, and the radioisotopes are highly accessible without complex chemistry. As such the majority of oncolytic viruses generated in their labs contain a signature NIS reporter gene. Together with physicist Dr. Mike O’Connor, an expert in SPECT molecular imaging, they are strong advocates of incorporating molecular imaging in drug development and adoption of nuclear imaging in preclinical and clinical research to accelerate drug development. Today, NIS expressing measles virus and VSV are being tested in a number of Phase I and II clinical trials in patients with treatment refractory cancers.
Imanis is always open to inquiries from highly motivated individuals keen to join the team of virologists, imaging scientists and operations personnel. Please view our Careers or send inquiries to email@example.com.